Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Artificial antigen presenting cells and methods of use

A technology of artificial antigens and cells, applied in the fields of biochemical equipment and methods, animal cells, cancer antigen components, etc., can solve problems such as expensive, time-consuming, and limited standardization of treatment plans.

Pending Publication Date: 2020-09-25
RUBIUS THERAPEUTICS
View PDF24 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, certain challenges have been encountered with native APCs such as DCs, including a lack of knowledge about optimal antigen-loaded DCs and mixed results found in clinical trials (Steenblock E.R. et al., Expert Opin. Biol. Ther .2009;9:451-464; Melief CMJ Immunity.2008;29:372-383; Palucka K. and Banchereau J. Immunity.2013;39:38-48)
Additionally, isolation and ex vivo stimulation of autologous DCs is time-consuming and expensive, and the quality of ex vivo-generated DCs may be variable (Steenblock E.R. et al. 2009; Kim J.V. et al. Nat. Biotechnol. 2004; 22: 403-410)
Thus, the use of patient-derived autologous DCs limits the standardization of DC-based regimens (Steenblock E.R. et al. 2009; Kim J.V. et al. 2004)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Artificial antigen presenting cells and methods of use
  • Artificial antigen presenting cells and methods of use
  • Artificial antigen presenting cells and methods of use

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[1090] Formulations of the pharmaceutical compositions described herein can be prepared by any method known or later developed in the art of pharmacology. In general, such preparation methods include the step of bringing into association the active ingredient with the carrier or one or more other accessory ingredients, and then, if necessary or desired, shaping or packaging the product into desired unit-dose or multi-dose units.

[1091] Although the description of pharmaceutical compositions provided herein is primarily directed to pharmaceutical compositions suitable for ethical administration to humans, those skilled in the art will appreciate that such compositions are generally suitable for administration to all species of animals. Modifications of pharmaceutical compositions suitable for human administration in order to adapt the compositions for administration to various animals are well known and can be devised and performed by only ordinary, if any, experimentation by ...

Embodiment 1

[1124] Example 1. Generation of Erythroid Cells Genetically Engineered to Express MOG-MHCII-GPA Fusion Protein

[1125] result

[1126] Erythroid cells were transduced to express a fusion protein comprising an exogenous antigenic peptide (myelin oligodendrocyte glycoprotein (MOG)), fused with an exogenous antigen-presenting polypeptide (especially MHCII), and GPA spanning Fusion of a membrane domain (GPA) that acts as a membrane anchor (MOG-MHCII-GPA). Figure 1A A schematic diagram of the design used to express MOG peptide and MHCII as a single-chain fusion is shown, wherein the exogenous peptide (MOG) is linked to the MHCIIβ chain linked to the MHCIIα chain linked to the GPA membrane anchor. Cell culture and transduction were performed as described in the "Methods" section below to generate erythroid cells expressing MOG presented by MHCII on the cell surface anchored with the GPA transmembrane domain.

[1127] Conjugation of allophycocyanin (APC)-labeled or phycoerythrin (...

Embodiment 2

[1137] Example 2. Generation and in vitro validation of erythroid cells genetically engineered to co-express MOG-MHCII-GPA fusion proteins and co-inhibitory polypeptides

[1138] result

[1139] As described in Example 1, erythroid cells were transduced to express a fusion protein comprising exogenous antigenic peptide (MOG), fused to exogenous antigen-presenting polypeptide (MHCII), and GPA transmembrane domain (GPA ) fusion (MOG-MHCII-GPA). Erythroid cells were co-transduced to additionally express the exogenous co-inhibitory peptide PD-L1. Cell culture and transduction were performed as described in the Methods section below to generate erythroid cells expressing MOG presented by MHCII on the cell surface, anchored with the GPA transmembrane domain, and co-expressing PD-L1.

[1140] As also described in Example 1, the incorporation of APC-labeled or PE-labeled anti-MHCII antibodies was used to verify the expression of MHCII antigen-presenting peptides in engineered erythr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure relates to artificial antigen presenting cells (aAPCs), in particular engineered erythroid cells and enucleated cells (e.g. enucleated erythroid cells and platelets), that are engineered to activate or suppress T cells.

Description

[0001] related application [0002] This application claims U.S. Provisional Patent Application No. 62 / 610,149, filed December 23, 2017, U.S. Provisional Patent Application No. 62 / 650,250, filed March 29, 2018, U.S. Provisional Patent Application No. 62 / 650,250, filed May 1, 2018 Patent Application No. 62 / 665,445, filed June 4, 2018 U.S. Provisional Patent Application No. 62 / 680,544, filed June 18, 2018 U.S. Provisional Patent Application No. 62 / 686,656, filed June 21, 2018 U.S. Provisional Patent Application No. 62 / 688,324, filed June 29, 2018, U.S. Provisional Patent Application No. 62 / 692,623, filed October 12, 2018, U.S. Provisional Patent Application No. 62 / 745,253, filed October 12, 2018 The priority of US Provisional Patent Application No. 62 / 757,741, filed November 8, each of which is hereby incorporated by reference in its entirety for all purposes. [0003] sequence listing [0004] This application contains a Sequence Listing that has been submitted electronically i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/00A61K39/12
CPCA61K39/00A61K39/0008A61K39/0011A61K39/12C12N2710/16234C12N2710/20034A61K39/001192A61K39/4611A61K39/4634A61K39/464492A61K39/4622A61K39/4621A61K39/4644A61K39/464414C12N5/0637A61K39/4637A61K39/464838A61K39/4615A61K2239/57A61K39/464496A61K35/15A61K39/461A61K35/18C12N5/0644C12N5/0641A61K35/19A61K39/02A61P37/00A61P35/00A61P31/00A61P37/08A61K2039/5154A61K2039/5156
Inventor T.J.威克汉姆T.F-Y.陈S.埃洛尔R.S.萨尔瓦特N.J.道登
Owner RUBIUS THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com